In the early 20th century, Lallemand focused on the production of yeast for the North American baking industry. Using the acquired knowledge and the technological assets in microbiology and fermentation as a base, it has come to serve the needs of other industries through the production of specialty yeast, bacteria and derivatives.

Today, Lallemand is a world leader in supplying yeast and bacteria to various industries, including human health and nutrition.

**PRODUCTION**
Lallemand Human Nutrition specializes in supplying mineral- and vitamin-rich yeast and probiotic bacteria, as well as cranberry, cocoa, herbal and other antioxidant-rich ingredients, in addition to proprietary strains of bacteria and yeast formulations for various digestive and immunity health conditions, plus bacterial lysate used to improve patients’ general or specific immunity.

Lallemand’s ongoing investments in optimizing production conditions have earned the two principal bacteria-manufacturing sites in France and Canada the prestigious Good Manufacturing Practices (GMP) certification from Health Canada and from the International Conference on Harmonisation for Active Pharmaceutical Ingredients (ICHQ7A), the GMP Pharma certification for Active Pharmaceutical Ingredients, and the Drug Product Pharma for finished products from the AFSSA.

**RESEARCH AND DEVELOPMENT**
From the beginning, Lallemand Human Nutrition has been committed to continuous innovation. Our main areas of research focus on fermentation and strain improvement processes, and on factors influencing the technological performance of our strains. The acquisition of Institut Rosell in 1998 paved the way to exciting new possibilities in the area of research henceforth focused on the scientific and clinical documentation of probiotic formulations designed specifically for their health benefits.

Dedicated to continuously improving scientific performance, throughout the years Lallemand has forged numerous alliances and collaborative relationships with international public and private partners, which include universities, hospitals, pharmaceutical companies and world-renowned research centres located primarily in North America and Europe (including McGill University, Université de Montréal, University of Saskatchewan, etc.).
the Agriculture and Agri-Food Canada Food Research and Development Centre in Saint-Hyacinthe, the National Research Council Biotechnology Research Institute, INRA Toulouse, Rome University, University of New South Wales, the Assistance publique – Hôpitaux de Paris [AP-HP] with the CHU [university hospital] Louis-Mourier in Colombes, CHU Nice and the CHU Rouen, the University of Milan Department of Public Health – Microbiology – Virology, Biofortis Nantes, and the Hospital for Sick Children affiliated with the University of Toronto, among others). The fundamental purpose of these affiliations is to bring the best expertise to Lallemand’s strains and finished products in the areas of strain grading, pharmacological and analysis of the mode of action, toxicological assessment, as well as pre-clinical and clinical trials performed on our probiotic yeast and bacteria and on our mineral-enriched yeasts.

ENTITIES

INSTITUT ROSELL

Institut Rosell is a Canadian company, internationally renowned, which specializes in the development, production and marketing of probiotics for human nutrition applications.

With its main offices and research laboratories located in Montréal (Canada) and Toulouse (France), Institut Rosell has become a leader in the development and application of living microorganisms, and has implemented a variety of research programs aimed at better understanding the properties, mechanisms and effects of its line of probiotics on human health.

The principal offerings of Institut Rosell are comprised of scientifically documented products based on probiotic strains derived primarily from the Rosell collection. These products include formulations such as Lacidofil®, Lallflor®, Probiokid® and Probio’stick®, among others, as well as specific strains under the ROSELL or LAFTI trademark. They are marketed in numerous countries either as over-the-counter drugs or as dietary supplements.

LALLEMAND HEALTH INGREDIENTS

Lallemand Health Ingredients (LHI) manages the sales and service of strategic ingredients for the dietary supplement and functional food industry. LHI works in close contact with customers to develop and formulate supplements for a variety of health segments. This entails regulatory support, advice on the choice of raw materials and the positioning of products. LHI is based in Copenhagen (Denmark) and Montréal, servicing the European and North American markets.

LHI offers Lallemand probiotic bacteria, a complete line of highly bioavailable mineral- and vitamin-enriched yeasts (Lalmin®), and a range of plant extracts, including a range of premium cranberry powders and extracts from Decas Botanical Synergies.

LALLEMAND PHARMA INTERNATIONAL

Based in Zug (Switzerland), Lallemand Pharma International (LPI) is dedicated exclusively to the clinical studies, registration, marketing and sales of pharmaceutical products based on high quality mechanical bacterial lysates produced by Lallemand. The primary objective of LPI is to develop and sell a range of bacterial lysates (Ismigen®, Immubron®, Bromunyl®, Respibron® and Bactovax®) produced at Lallemand’s Saint-Simon facility in France. The specificity of these lysates is that they are produced from a complete range of pathogenic bacteria that are inactivated through mechanical lysis. This original and unique process gives the drug a far stronger immunogenic power than other lysates currently on the market. The company’s key product – Ismigen® – is recommended in the prophylaxis and treatment of chronic and acute respiratory infections and diseases. Backed by numerous clinical trials, Ismigen® is already registered and successfully marketed in numerous countries.

www.institut-rosell-lallemand.com
www.lallemandhi.com
www.lallemandpharma.com